Do α-adrenergic mechanisms regulate spontaneous or opiate-modulated pulsatile luteinizing hormone secretion in man?

Johannes D Veldhuis, A. D. Rogol, F. A. Williams, M. L. Johnson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Brain noradrenergic mechanisms participate in the excitatory control of episodic LH release in many experimental animals, including the nonhuman primate. In addition, augmentation of pulsatile LH release in the rodent in response to opiate receptor antagonists is dependent upon intact central noradrenergic pathways. The applicability of these tenets to humans is not known. We tested the excitatory influence of brain noradrenergic systems on pulsatile LH secretion in normal men by administering phenoxybenzamine (an irreversible, preferentially postsynaptic, α1-receptor blocker) or α-methyldopa (an inhibitor of brain adrenergic transmission). Five normal men underwent repetitive (every 20 min) venous sampling for 8 h to characterize episodic LH release quantitatively under basal conditions and after the administration of naltrexone, a potent opiate receptor antagonist which stimulates pulsatile LH release. Subjects received saline, phenoxybenzamine (1 mg/kg, iv, over 90 min), or α-methyldopa (250 mg, orally, every 6 h). The following parameters of spontaneous episodic LH secretion were not altered after phenoxybenzamine or α-methyldopa administration: mean and integrated serum LH concentrations, LH pulse frequency, LH pulse amplitude (percentage or milliinternational units per ml increment), and absolute peak serum LH values. In addition, the administration of adrenergic inhibitors did not impede the capacity of naltrexone to significantly augment pulsatile LH secretion in these subjects. We conclude that in the doses used, phenoxybenzamine and α-methyldopa do not alter spontaneous or opiate-modulated episodic LH release in normal men.

Original languageEnglish (US)
Pages (from-to)1292-1296
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume57
Issue number6
StatePublished - 1983
Externally publishedYes

Fingerprint

Opiate Alkaloids
Methyldopa
Phenoxybenzamine
Luteinizing Hormone
Adrenergic Agents
Brain
Naltrexone
Opioid Receptors
Serum
Primates
Rodentia
Animals
Sampling

ASJC Scopus subject areas

  • Biochemistry

Cite this

Do α-adrenergic mechanisms regulate spontaneous or opiate-modulated pulsatile luteinizing hormone secretion in man? / Veldhuis, Johannes D; Rogol, A. D.; Williams, F. A.; Johnson, M. L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 57, No. 6, 1983, p. 1292-1296.

Research output: Contribution to journalArticle

Veldhuis, Johannes D ; Rogol, A. D. ; Williams, F. A. ; Johnson, M. L. / Do α-adrenergic mechanisms regulate spontaneous or opiate-modulated pulsatile luteinizing hormone secretion in man?. In: Journal of Clinical Endocrinology and Metabolism. 1983 ; Vol. 57, No. 6. pp. 1292-1296.
@article{c2503bc0e2ef4f3ea96da6ff49b60d55,
title = "Do α-adrenergic mechanisms regulate spontaneous or opiate-modulated pulsatile luteinizing hormone secretion in man?",
abstract = "Brain noradrenergic mechanisms participate in the excitatory control of episodic LH release in many experimental animals, including the nonhuman primate. In addition, augmentation of pulsatile LH release in the rodent in response to opiate receptor antagonists is dependent upon intact central noradrenergic pathways. The applicability of these tenets to humans is not known. We tested the excitatory influence of brain noradrenergic systems on pulsatile LH secretion in normal men by administering phenoxybenzamine (an irreversible, preferentially postsynaptic, α1-receptor blocker) or α-methyldopa (an inhibitor of brain adrenergic transmission). Five normal men underwent repetitive (every 20 min) venous sampling for 8 h to characterize episodic LH release quantitatively under basal conditions and after the administration of naltrexone, a potent opiate receptor antagonist which stimulates pulsatile LH release. Subjects received saline, phenoxybenzamine (1 mg/kg, iv, over 90 min), or α-methyldopa (250 mg, orally, every 6 h). The following parameters of spontaneous episodic LH secretion were not altered after phenoxybenzamine or α-methyldopa administration: mean and integrated serum LH concentrations, LH pulse frequency, LH pulse amplitude (percentage or milliinternational units per ml increment), and absolute peak serum LH values. In addition, the administration of adrenergic inhibitors did not impede the capacity of naltrexone to significantly augment pulsatile LH secretion in these subjects. We conclude that in the doses used, phenoxybenzamine and α-methyldopa do not alter spontaneous or opiate-modulated episodic LH release in normal men.",
author = "Veldhuis, {Johannes D} and Rogol, {A. D.} and Williams, {F. A.} and Johnson, {M. L.}",
year = "1983",
language = "English (US)",
volume = "57",
pages = "1292--1296",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Do α-adrenergic mechanisms regulate spontaneous or opiate-modulated pulsatile luteinizing hormone secretion in man?

AU - Veldhuis, Johannes D

AU - Rogol, A. D.

AU - Williams, F. A.

AU - Johnson, M. L.

PY - 1983

Y1 - 1983

N2 - Brain noradrenergic mechanisms participate in the excitatory control of episodic LH release in many experimental animals, including the nonhuman primate. In addition, augmentation of pulsatile LH release in the rodent in response to opiate receptor antagonists is dependent upon intact central noradrenergic pathways. The applicability of these tenets to humans is not known. We tested the excitatory influence of brain noradrenergic systems on pulsatile LH secretion in normal men by administering phenoxybenzamine (an irreversible, preferentially postsynaptic, α1-receptor blocker) or α-methyldopa (an inhibitor of brain adrenergic transmission). Five normal men underwent repetitive (every 20 min) venous sampling for 8 h to characterize episodic LH release quantitatively under basal conditions and after the administration of naltrexone, a potent opiate receptor antagonist which stimulates pulsatile LH release. Subjects received saline, phenoxybenzamine (1 mg/kg, iv, over 90 min), or α-methyldopa (250 mg, orally, every 6 h). The following parameters of spontaneous episodic LH secretion were not altered after phenoxybenzamine or α-methyldopa administration: mean and integrated serum LH concentrations, LH pulse frequency, LH pulse amplitude (percentage or milliinternational units per ml increment), and absolute peak serum LH values. In addition, the administration of adrenergic inhibitors did not impede the capacity of naltrexone to significantly augment pulsatile LH secretion in these subjects. We conclude that in the doses used, phenoxybenzamine and α-methyldopa do not alter spontaneous or opiate-modulated episodic LH release in normal men.

AB - Brain noradrenergic mechanisms participate in the excitatory control of episodic LH release in many experimental animals, including the nonhuman primate. In addition, augmentation of pulsatile LH release in the rodent in response to opiate receptor antagonists is dependent upon intact central noradrenergic pathways. The applicability of these tenets to humans is not known. We tested the excitatory influence of brain noradrenergic systems on pulsatile LH secretion in normal men by administering phenoxybenzamine (an irreversible, preferentially postsynaptic, α1-receptor blocker) or α-methyldopa (an inhibitor of brain adrenergic transmission). Five normal men underwent repetitive (every 20 min) venous sampling for 8 h to characterize episodic LH release quantitatively under basal conditions and after the administration of naltrexone, a potent opiate receptor antagonist which stimulates pulsatile LH release. Subjects received saline, phenoxybenzamine (1 mg/kg, iv, over 90 min), or α-methyldopa (250 mg, orally, every 6 h). The following parameters of spontaneous episodic LH secretion were not altered after phenoxybenzamine or α-methyldopa administration: mean and integrated serum LH concentrations, LH pulse frequency, LH pulse amplitude (percentage or milliinternational units per ml increment), and absolute peak serum LH values. In addition, the administration of adrenergic inhibitors did not impede the capacity of naltrexone to significantly augment pulsatile LH secretion in these subjects. We conclude that in the doses used, phenoxybenzamine and α-methyldopa do not alter spontaneous or opiate-modulated episodic LH release in normal men.

UR - http://www.scopus.com/inward/record.url?scp=0021014143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021014143&partnerID=8YFLogxK

M3 - Article

C2 - 6313736

AN - SCOPUS:0021014143

VL - 57

SP - 1292

EP - 1296

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -